Amal Melhem-Bertrandt

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Early onset HER2-positive breast cancer is associated with germline TP53 mutations
    Amal Melhem-Bertrandt
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:908-13. 2012
  2. pmc Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer
    Amal Melhem-Bertrandt
    The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
    J Clin Oncol 29:2645-52. 2011
  3. pmc Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer
    Soley Bayraktar
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:2385-93. 2012
  4. doi Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer
    Rashmi K Murthy
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 120:1932-8. 2014
  5. doi Leptomeningeal disease and breast cancer: the importance of tumor subtype
    Sausan Abouharb
    Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Breast Cancer Res Treat 146:477-86. 2014

Collaborators

Detail Information

Publications5

  1. pmc Early onset HER2-positive breast cancer is associated with germline TP53 mutations
    Amal Melhem-Bertrandt
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:908-13. 2012
    ..Germline TP53 mutations predispose to early onset breast cancer in women and are associated with Li-Fraumeni syndrome. Published data on the pathological characteristics of breast cancer among women with TP53 mutations is limited...
  2. pmc Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer
    Amal Melhem-Bertrandt
    The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
    J Clin Oncol 29:2645-52. 2011
    ..To examine the association between beta-blocker (BB) intake, pathologic complete response (pCR) rates, and survival outcomes in patients with breast cancer treated with neoadjuvant chemotherapy...
  3. pmc Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer
    Soley Bayraktar
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:2385-93. 2012
    ....
  4. doi Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer
    Rashmi K Murthy
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 120:1932-8. 2014
    ....
  5. doi Leptomeningeal disease and breast cancer: the importance of tumor subtype
    Sausan Abouharb
    Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Breast Cancer Res Treat 146:477-86. 2014
    ..30; 95 %CI 1.98-5.52). LMD carries a dismal prognosis. Modest survival differences by tumor subtype were seen. Patients with HER2+BC had the best outcome. There is an urgent need to develop effective treatment strategies. ..